Re: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
Mirchandani
D
D
Muggia
F
F
D000328:Adult; D000367:Age Factors; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D044383:Black People; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic / Q000379:methods; D018572:Disease-Free Survival; D005006:Ethnicity; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis / Q000187:drug effects; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D018579:Patient Selection; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis / Q000187:drug effects; D012306:Risk; D018570:Risk Assessment; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use*; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use; D019851:Thrombophilia / Q000139:chemically induced / Q000401:mortality; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D009363:Neoplasm Proteins; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen